Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Indications for autologous stem cell transplantation in AML

Norbert-Claude Gorin • 23 Apr 2023
EBMT 2023
Acute Myeloid Leukemia Acute Promyelocytic Leukemia Leukemia Rare Diseases

Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the current indications for autologous stem cell transplantation (autoSCT) in acute myeloid leukemia (AML). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Norbert-Claude Gorin

1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
1:08
The progress of the EBMT & key ongoing projects
Norbert-Claude Gorin • 23 Apr 2023
1:39
The evolution of stem cell transplantation
Norbert-Claude Gorin • 23 Apr 2023
1:13
Outcomes following FD & NFD related donor haplo transplantation for patients with acute leukemias
Norbert-Claude Gorin • 23 Apr 2023

Related Videos

3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals